Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?

References

• Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2012;121(12):4600-9
   Web of Science ®Google Scholar
• Dropulic LK, Cohen JI. The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines 2012;11(12):1429-40
   PubMed Web of Science ®Google Scholar
• Cohen J. Immunology. Painful failure of promising genital herpes vaccine. Science 2010;330(6002):304
   PubMed Web of Science ®Google Scholar
• Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012;366(1):34-43
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21):1652-61
   PubMed Web of Science ®Google Scholar
• Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999;282(4):331-40
   PubMed Web of Science ®Google Scholar
• Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997;176(5):1129-34
   PubMed Web of Science ®Google Scholar
• Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343(8911):1460-3
   PubMed Web of Science ®Google Scholar
• Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990;161(4):653-60
   PubMed Web of Science ®Google Scholar
• Watson RJ, Enquist LW. Genetically engineered herpes simplex virus vaccines. Prog Med Virol 1985;31:84-108
   PubMedGoogle Scholar
• Watson RJ, Weis JH, Salstrom JS, Enquist LW. Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli. Science 1982;218(4570):381-4
   PubMed Web of Science ®Google Scholar
• Halford WP, Gebhardt BM. Host interferon: a silent partner in the regulation of herpes simplex virus latency. In: Mossman KL, editor. Viruses and interferon: current research. Horizon Scientific Press; Hethersett, UK: 2011. p. 85-11
   Google Scholar
• Ledford H. Failed herpes vaccine puzzles virologists. Nature 2012; doi:10.1038/nature.2012.9739
   Google Scholar
• Stanberry LR, Bernstein DI, Burke RL, et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155(5):914-20
   PubMed Web of Science ®Google Scholar
• McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996;93(21):11414-20
   PubMed Web of Science ®Google Scholar
• Bourne N, Bravo FJ, Francotte M, et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003;187(4):542-9
   PubMed Web of Science ®Google Scholar
• Bourne N, Milligan GN, Stanberry LR, et al. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 2005;192(12):2117-23
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Earwood JD, Bravo FJ, et al. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 2011;29(11):2071-8
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Farley N, Bravo FJ, et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 2010;28(21):3748-53
   PubMed Web of Science ®Google Scholar
• Laing KJ, Magaret AS, Mueller DE, et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 2010;30(5):703-22
   PubMed Web of Science ®Google Scholar
• Gilman SC, Docherty JJ, Rawls WE. Antibody responses in humans to individual proteins of herpes simplex viruses. Infect Immun 1981;34(3):880-7
   PubMed Web of Science ®Google Scholar
• Laing KJ, Dong L, Sidney J, et al. Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol 2012;167(1):47-58
   PubMed Web of Science ®Google Scholar
• Posavad CM, Remington M, Mueller DE, et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 2010;184(6):3250-9
   PubMed Web of Science ®Google Scholar
• Hosken N, McGowan P, Meier A, et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 2006;80(11):5509-15
   PubMed Web of Science ®Google Scholar
• Koelle DM, Schomogyi M, McClurkan C, et al. CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J Virol 2000;74(23):11422-5
   PubMed Web of Science ®Google Scholar
• Ashley R, Mack K, Critchlow C, et al. Differential effect of systemic acyclovir treatment of genital HSV-2 infections on antibody responses to individual HSV-2 proteins. J Med Virol 1988;24(3):309-19
   PubMed Web of Science ®Google Scholar
• Ashley R, Mertz GJ, Corey L. Detection of asymptomatic herpes simplex virus infections after vaccination. J Virol 1987;61(2):264-8
   PubMed Web of Science ®Google Scholar
• Ashley R, Mertz G, Clark H, et al. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 1985;56(2):475-81
   PubMed Web of Science ®Google Scholar
• Wald A, Koelle DM, Fife K, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011;29(47):8520-9
   PubMed Web of Science ®Google Scholar
• Skoberne M, Cardin R, Lee A, et al. An adjuvanted herpes simplex virus type 2 (HSV-2) subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J Virol 2013;87(7):3930-42
   PubMed Web of Science ®Google Scholar
• Available from: http://www.antigenics.com/docs/press-releases/2013/herpv-vaccine-for-genital-herpes-meets-primary-endpoint.php 2013
   Google Scholar
• Available from: http://www.genocea.com/publications/files/Interscience%20Conference%20on%20Antimicrobial%20Agents%20and%20Chemotherapy%20%28ICAAC%29%20Denver%20CO,%20September%2010-13,%202013.pdf 2013
   Google Scholar
• Johnston C, Koelle DM, Wald A. Current status and prospects for development of an HSV vaccine. Vaccine 2014;32(14):1553-60
   PubMed Web of Science ®Google Scholar
• Dasgupta G, Chentoufi AA, Nesburn AB, et al. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines 2009;8(8):1023-35
   PubMed Web of Science ®Google Scholar
• Haddow LJ, Mindel A. Genital herpes vaccines–cause for cautious optimism. Sex Health 2006;3(1):1-4
   PubMedGoogle Scholar
• Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci 2005;10:966-74
   PubMed Web of Science ®Google Scholar
• Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004;11(3):437-45
   PubMedGoogle Scholar
• Cunningham AL, Mikloska Z. The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 2001;8(Suppl 1):6A-10A
   PubMedGoogle Scholar
• Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000;30(3):549-66
   PubMed Web of Science ®Google Scholar
• Hall MJ, Katrak K. The quest for a herpes simplex virus vaccine: background and recent developments. Vaccine 1986;4(3):138-50
   PubMed Web of Science ®Google Scholar
• Wenz C. Genital herpes: vaccines show the way. Nature 1983;303(5919):648-9
   PubMed Web of Science ®Google Scholar
• Gunby P. Genital herpes research: many aim to tame maverick virus. JAMA 1983;250(18):2417-19; 2423–2414, 2427
   PubMed Web of Science ®Google Scholar
• Delagrave S, Hernandez H, Zhou C, et al. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model. PLoS One 2012;7(10):e46714
   PubMed Web of Science ®Google Scholar
• Awasthi S, Zumbrun EE, Si H, et al. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol 2012;86(8):4586-98
   PubMed Web of Science ®Google Scholar
• Halford WP, Puschel R, Gershburg E, et al. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 2011;6(3):e17748
   Web of Science ®Google Scholar
• Hoshino Y, Pesnicak L, Dowdell KC, et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008;26(32):4034-40
   PubMed Web of Science ®Google Scholar
• Parr EL, Parr MB. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 1999;98(4):639-45
   PubMed Web of Science ®Google Scholar
• McDermott MR, Smiley JR, Leslie P, et al. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 1984;51(3):747-53
   PubMed Web of Science ®Google Scholar
• Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006;344(1):230-9
   PubMed Web of Science ®Google Scholar
• Schrimpf JE, Tu EM, Wang H, et al. B7 costimulation molecules encoded by replication-defective, vhs-deficient HSV-1 improve vaccine-induced protection against corneal disease. PLoS One 2011;6(8):e22772
   Web of Science ®Google Scholar
• Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997;175(1):16-25
   PubMed Web of Science ®Google Scholar
• Vagvala SP, Thebeau LG, Wilson SR, Morrison LA. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice. J Virol 2009;83(2):953-60
   PubMed Web of Science ®Google Scholar
• Cohen JI. The varicella-zoster virus genome. Curr Top Microbiol Immunol 2010;342:1-14
   PubMed Web of Science ®Google Scholar
• Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008;197(Suppl 2):S165-9
   PubMed Web of Science ®Google Scholar
• Quinlivan M, Breuer J, Schmid DS. Molecular studies of the Oka varicella vaccine. Expert Rev Vaccines 2011;10(9):1321-36
   PubMed Web of Science ®Google Scholar
• Halford WP, Puschel R, Rakowski B. Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS One 2010;5(8):e12251
   Web of Science ®Google Scholar
• Halford WP, Weisend C, Grace J, et al. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol J 2006;3:44
   PubMed Web of Science ®Google Scholar
• Halford WP, Geltz J, Gershburg E. Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS One 2013;8(6):e65523
   Web of Science ®Google Scholar
• Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005;79(1):410-18
   PubMed Web of Science ®Google Scholar
• Xu F, Gee JM, Naleway A, et al. Incidence of neonatal herpes simplex virus infections in two managed care organizations: implications for surveillance. Sex Transm Dis 2008;35(6):592-8
   PubMed Web of Science ®Google Scholar
• Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol 2007;196(1):43.e41-6
   Web of Science ®Google Scholar
• Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296(8):964-73
   PubMed Web of Science ®Google Scholar
• Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40(3):187-93
   PubMed Web of Science ®Google Scholar
• CDC. Seroprevalence of herpes simplex virus type 2 among persons aged 14–49 years–United States, 2005–2008. MMWR Morb Mortal Wkly Rep 2010;59(15):456-9
   PubMedGoogle Scholar
• Gottlieb SL, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004;190(6):1059-67
   PubMed Web of Science ®Google Scholar
• Solomon L, Cannon MJ, Reyes M, et al. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. Sex Transm Infect 2003;79(6):456-9
   PubMed Web of Science ®Google Scholar
• Scott DA, Coulter WA, Lamey PJ. Oral shedding of herpes simplex virus type 1: a review. J Oral Pathol Med 1997;26(10):441-7
   PubMed Web of Science ®Google Scholar
• Buddingh GJ, Schrum DI, Lanier JC, Guidry DJ. Studies of the natural history of herpes simplex virus infections. Pediatrics 1953;11:593-605
   Web of Science ®Google Scholar
• Bertke AS, Patel A, Krause PR. Herpes simplex virus latency-associated transcript sequence downstream of the promoter influences type-specific reactivation and viral neurotropism. J Virol 2007;81(12):6605-13
   PubMed Web of Science ®Google Scholar
• Bren L. Genital herpes: a hidden epidemic. FDA Consum 2002;36(2):10-16
   PubMedGoogle Scholar
• Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Pediatr Clin North Am 2013;60(2):351-65
   PubMed Web of Science ®Google Scholar
• Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 2006;20(1):73-83
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J Clin Invest 2002;110(2):145-51
   PubMed Web of Science ®Google Scholar
• Morein B, Merza M. Vaccination against herpesvirus, fiction or reality? Scand J Infect Dis 1991;80(Suppl):110-18
   Google Scholar
• Centifanto-Fitzgerald YM, Rayfield M, Tian PY, Kaufman HE. Herpes simplex virus latency in the rabbit trigeminal ganglia: ganglionic superinfection. Proc Soc Exp Biol Med 1985;179(1):55-67
   PubMed Web of Science ®Google Scholar
• Centifanto-Fitzgerald YM, Varnell ED, Kaufman HE. Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains. Infect Immun 1982;35(3):1125-32
   PubMed Web of Science ®Google Scholar
• Meignier B, Norrild B, Roizman B. Colonization of murine ganglia by a superinfecting strain of herpes simplex virus. Infect Immun 1983;41(2):702-8
   PubMed Web of Science ®Google Scholar
• Sandstrom IK, Foster CS, Wells PA, et al. Previous immunization of mice with herpes simplex virus type-1 strain MP protects against secondary corneal infection. Clin Immunol Immunopathol 1986;40(2):326-34
   PubMedGoogle Scholar
• Thompson RL, Nakashizuka M, Stevens JG. Vaccine potential of a live avirulent herpes simplex virus. Microb Pathog 1986;1(4):409-16
   PubMed Web of Science ®Google Scholar
• Parr MB, Parr EL. Protective immunity against HSV-2 in the mouse vagina. J Reprod Immunol 1997;36(1-2):77-92
   PubMed Web of Science ®Google Scholar
• Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998;160(12):6093-100
   PubMed Web of Science ®Google Scholar
• Morello CS, Kraynyak KA, Levinson MS, et al. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 2012;30(46):6541-50
   PubMed Web of Science ®Google Scholar
• Shlapobersky M, Marshak JO, Dong L, et al. Vaxfectin(R)-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol 2012;93:1305-15
   PubMed Web of Science ®Google Scholar
• Khodai T, Chappell D, Christy C, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 2011;18(10):1702-9
   PubMed Web of Science ®Google Scholar
• Brans R, Yao F. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol 2010;10:163
   PubMed Web of Science ®Google Scholar
• Weir JP, Bennett M, Allen EM, et al. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J Gen Virol 1989;70(Pt 10):2587-94
   PubMedGoogle Scholar
• Chentoufi AA, Dasgupta G, Christensen ND, et al. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol 2010;184(5):2561-71
   PubMed Web of Science ®Google Scholar
• Skinner GR, Turyk ME, Benson CA, et al. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol (Berl) 1997;186(1):31-6
   PubMed Web of Science ®Google Scholar
• Skinner GR, Buchan A, Hartley CE, et al. The preparation, efficacy and safety of ‘antigenoid’ vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects. Med Microbiol Immunol 1980;169(1):39-51
   PubMed Web of Science ®Google Scholar
• Aurelian L, Kokuba H, Smith CC. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 1999;17(15–16):1951-63
   PubMed Web of Science ®Google Scholar
• Orr MT, Orgun NN, Wilson CB, Way SS. Cutting Edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 2007;178(8):4731-5
   PubMed Web of Science ®Google Scholar
• Meseda CA, Stout RR, Weir JP. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D. Viral Immunol 2006;19(2):250-9
   PubMed Web of Science ®Google Scholar
• Zheng B, Graham FL, Johnson DC, et al. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 1993;11(12):1191-8
   PubMed Web of Science ®Google Scholar
• Johnson DC. Adenovirus vectors as potential vaccines against herpes simplex virus. Rev Infect Dis 1991;13(Suppl 11):S912-16
   Google Scholar
• Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158(3):602-14
   PubMed Web of Science ®Google Scholar
• Mori I, Liu B, Goshima F, et al. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2. Microbes Infect 2005;7(15):1492-500
   PubMed Web of Science ®Google Scholar
• Osorio Y, Ghiasi H. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes. J Virol 2003;77(10):5774-83
   PubMed Web of Science ®Google Scholar
• Veselenak RL, Shlapobersky M, Pyles RB, et al. Vaxfectin((R))-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012;30(49):7046-51
   PubMed Web of Science ®Google Scholar
• Domingo C, Gadea I, Pardeiro M, et al. Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D. Vaccine 2003;21(25–26):3565-74
   PubMed Web of Science ®Google Scholar
• Dutton JL, Li B, Woo WP, et al. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLoS One 2013;8(10):e76407
   Web of Science ®Google Scholar
• Chiuppesi F, Vannucci L, De Luca A, et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol 2012;86(12):6563-74
   PubMed Web of Science ®Google Scholar
• Natuk RJ, Cooper D, Guo M, et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 2006;80(9):4447-57
   PubMed Web of Science ®Google Scholar
• Mattion NM, Reilly PA, Camposano E, et al. Characterization of recombinant polioviruses expressing regions of rotavirus VP4, hepatitis B surface antigen, and herpes simplex virus type 2 glycoprotein D. J Virol 1995;69(8):5132-7
   PubMed Web of Science ®Google Scholar
• Heineman TC, Connelly BL, Bourne N, et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995;69(12):8109-13
   PubMed Web of Science ®Google Scholar
• Karem KL, Bowen J, Kuklin N, Rouse BT. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 1997;78(Pt 2):427-34
   PubMedGoogle Scholar
• Bernstein D. Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Rev Vaccines 2005;4(5):615-27
   PubMed Web of Science ®Google Scholar
• Higgins TJ, Herold KM, Arnold RL, et al. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J Infect Dis 2000;182(5):1311-20
   PubMed Web of Science ®Google Scholar
• Available from: http://www.gsk.com/media/press-releases/2010/gsk-provides-update-on-herpevac-trial-for-women-evaluating-simplirix-herpes-simplex-vaccine.html 2010
   Google Scholar
• Skinner GR, Fink C, Melling J, et al. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol 1992;180(6):305-20
   PubMed Web of Science ®Google Scholar
• Skinner GR, Fink CG, Cowan M, et al. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med Microbiol Immunol 1987;176(3):161-8
   PubMed Web of Science ®Google Scholar
• Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011;85(7):3461-72
   PubMed Web of Science ®Google Scholar
• Dolan BP, Bennink JR, Yewdell JW. Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands. Cell Mol Life Sci 2011;68(9):1481-9
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci 2001;114(Pt 5):845-51
   PubMed Web of Science ®Google Scholar
• Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204(3):595-603
   PubMed Web of Science ®Google Scholar
• Divito S, Cherpes TL, Hendricks RL. A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol Res 2006;36(1-3):119-26
   PubMed Web of Science ®Google Scholar
• Khanna KM, Lepisto AJ, Hendricks RL. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol 2004;25(5):230-4
   PubMed Web of Science ®Google Scholar
• Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985;151(3):420-36
   PubMed Web of Science ®Google Scholar
• Wharton M, Cochi SL, Williams WW. Measles, mumps, and rubella vaccines. Infect Dis Clin North Am 1990;4(1):47-73
   PubMedGoogle Scholar
• Mundle ST, Hernandez H, Hamberger J, et al. High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoS One 2013;8(2):e57224
   PubMed Web of Science ®Google Scholar
• Da Costa X, Kramer MF, Zhu J, et al. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000;74(17):7963-71
   PubMed Web of Science ®Google Scholar
• Ali SA, McLean CS, Boursnell ME, et al. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Cancer Res 2000;60(6):1663-70
   PubMed Web of Science ®Google Scholar
• Xiang Z, He Y. Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology. BMC Bioinformatics 2013;14(Suppl 4):S2
   PubMed Web of Science ®Google Scholar
• Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012;491:463-7
   PubMed Web of Science ®Google Scholar
• Hu K, He X, Yu F, et al. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis. Immunol Invest 2011;40(3):265-78
   PubMed Web of Science ®Google Scholar
• Awasthi S, Lubinski JM, Eisenberg RJ, et al. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine 2008;26(9):1195-203
   PubMed Web of Science ®Google Scholar
• Mihailescu R, Vitzu M, Brestoiu S. Treatment and prophylaxis of recurrent genital herpes using vaccinia immunostimulant (Antiherpin). Arch Roum Pathol Exp Microbiol 1990;49(4):315-21
   PubMedGoogle Scholar
• Skinner GR, Buchan A, Davies J, et al. A virus-particle vaccine prepared from bovine mammillitis virus against herpes genitalis. Comp Immunol Microbiol Infect Dis 1991;14(2):133-50
   PubMed Web of Science ®Google Scholar
• Moller A, Andersen PL, Korsager B, Black FT. [Yellow fever vaccination as prophylaxis of herpes labialis]. Ugeskr Laeger 1997;159(15):2228-9
   PubMedGoogle Scholar
• Schoub BD. Polio vaccine for the treatment of recurrent herpes simplex infections. S Afr Med J 1991;79(10):623
   PubMed Web of Science ®Google Scholar
• Use of oral poliovirus vaccine for unlicensed indications. CMAJ 1991;145(6):661
   PubMed Web of Science ®Google Scholar
• Wu JJ, Huang DB, Tyring SK. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 2004;64(2):79-83
   PubMed Web of Science ®Google Scholar
• Pyles RB, Higgins D, Chalk C, et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 2002;76(22):11387-96
   PubMed Web of Science ®Google Scholar
• The_HSV-040_Study_Group. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10–17 years of age: results from a randomised, controlled, double-blind trial. Vaccine 2013;31(51):6136-43
   PubMed Web of Science ®Google Scholar
• Tavares F, Cheuvart B, Heineman T, et al. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. Vaccine 2013;31(13):1759-64
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Clement F, Vandepapeliere P, et al. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. Hum Vaccin Immunother 2013;9(6):1254-62
   PubMed Web of Science ®Google Scholar
• Dervillez X, Qureshi H, Chentoufi AA, et al. Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes. J Immunol 2013;191(10):5124-38
   PubMed Web of Science ®Google Scholar
• Santana VC, Diniz MO, Cariri FA, et al. Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8(+) T cell responses and protective immunity. PLoS One 2013;8(8):e71322
   PubMed Web of Science ®Google Scholar
• de Bruyn G, Vargas-Cortez M, Warren T, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006;24(7):914-20
   PubMed Web of Science ®Google Scholar
• Douglas JM, Vontver LA, Stamm WE, et al. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes. Antimicrob Agents Chemother 1985;27(2):203-6
   PubMed Web of Science ®Google Scholar
• Fanta D, Dostal V, Reiss-Gutfreund R. [BCG therapy of recurrent herpes simplex type 1 and 2 (HSV-1 and 2)]. Z Hautkr 1977;52(21):1099-104
   PubMedGoogle Scholar
• Smolin G, Okumoto M, Meyer R, Belfort R Jr. Effect of immunization with attenuated Mycobacterium bovis (BCG) on experimental herpetic keratitis. Can J Ophthalmol 1975;10(3):385-90
   PubMed Web of Science ®Google Scholar
• Anderson FD, Ushijima RN, Larson CL. Recurrent herpes genitalis. Treatment with Mycobacterium bovis (BCG). Obstet Gynecol 1974;43(6):797-805
   PubMed Web of Science ®Google Scholar
• Macotela E, Alvarez-de la Rocha JB, Castillo-Rodriguez R, et al. [Management of recurrent genital herpes simplex with the Sabin triple vaccine]. Gac Med Mex 1979;115(10):461-3
   PubMedGoogle Scholar
• Garrel J, Millet P, Sonneck JM, et al. [Recurrent herpes: treatment using trivalent oral polio vaccine (author’s transl)]. Nouv Presse Med 1979;8(1):47
   PubMedGoogle Scholar
• Bierman SM. Sabin’s poliomyelitis vaccine in recurrent herpes simplex. Arch Dermatol 1978;114(7):1094-5
   PubMedGoogle Scholar
• Schoub BD. Smallpox vaccine for the treatment of recurrent herpes infection. S Afr Med J 1982;62(7):189
   PubMed Web of Science ®Google Scholar
• Kern AB, Schiff BL. Smallpox vaccinations in the management of recurrent herpes simplex: a controlled evaluation. J Invest Dermatol 1959;33:99-102
   PubMed Web of Science ®Google Scholar
• Le Goaster J, Gonzalo S, Bourée P, et al. Efficacy of the anti-VZV vaccine in HSV1 and HSV2 recurrent herpes simplex disease: a prospective study. Open Access J Clin Trials 2012;4:51-8
   Google Scholar
• Dunning R. Some observations on vaccination, and the inoculated cow-pox. London: 1800
   Google Scholar
• Lagrange PH, Hurtrel B, Stach JL. Vaccines against mycobacteria and other intracellular multiplying bacteria. Ann Inst Pasteur Immunol 1985;136D(2):151-62
   PubMedGoogle Scholar
• Waters WR, Palmer MV, Buddle BM, Vordermeier HM. Bovine tuberculosis vaccine research: historical perspectives and recent advances. Vaccine 2012;30(16):2611-22
   PubMed Web of Science ®Google Scholar
• Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990;162(2):313-21
   PubMed Web of Science ®Google Scholar
• Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008;205(1):7-12
   PubMed Web of Science ®Google Scholar
• Cohen J. AIDS research. Did Merck’s failed HIV vaccine cause harm? Science 2007;318(5853):1048-9
   PubMed Web of Science ®Google Scholar
• Cohen J. AIDS research. Promising AIDS vaccine’s failure leaves field reeling. Science 2007;318(5847):28-9
   PubMed Web of Science ®Google Scholar
• Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5(5):357-61
   PubMed Web of Science ®Google Scholar
• Casanova G, Cancela R, Alonzo L, et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002;70(4):235-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.businesswire.com/news/home/20100304005137/en/BioVex-Initiates-Phase-1-Clinical-Trial-Genital#.Uu6TQRAWK_o 2010
   Google Scholar
• Singh M, Carlson JR, Briones M, et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998;16(19):1822-7
   PubMed Web of Science ®Google Scholar
• Wizel B, Persson J, Thorn K, et al. Nasal and skin delivery of IC31((R))-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine 2012;30(29):4361-8
   PubMed Web of Science ®Google Scholar
• Kniskern PJ, Miller WJ. Hepatitis B vaccines: blueprints for vaccines of the future. Biotechnology 1992;20:177-204
   PubMedGoogle Scholar
• Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 2011;269(1):5-9
   PubMed Web of Science ®Google Scholar
• Halford WP. Towards an effective genital herpes vaccine: past lessons and future prospects. Future Virol 2007;2(1):1-6
   PubMed Web of Science ®Google Scholar
• Cockburn WC. The use of mixed diphtheria-pertussis-tetanus antigens. Bull World Health Organ 1955;13(3):409-22
   PubMedGoogle Scholar
• Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 2004;70:1-14
   Google Scholar
• Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008;59:381-95
   PubMed Web of Science ®Google Scholar
• Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003;16(1):96-113
   PubMed Web of Science ®Google Scholar
• Knickelbein JE, Khanna KM, Yee MB, et al. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008;322(5899):268-71
   PubMed Web of Science ®Google Scholar
• Khanna K, Bonneau R, Kinchington P, Hendricks R. Herpes simplex virus-specific memory CD8(+) T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003;18(5):593-603
   PubMed Web of Science ®Google Scholar
• Liu T, Khanna KM, Chen X, et al.8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000;191(9):1459-66
   PubMed Web of Science ®Google Scholar
• Speck P, Simmons A. Precipitous clearance of herpes simplex virus antigens from the peripheral nervous systems of experimentally infected C57BL/10 mice. J Gen Virol 1998;79(Pt 3):561-4
   PubMedGoogle Scholar
• Simmons A, Tscharke DC. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 1992;175(5):1337-44
   PubMed Web of Science ®Google Scholar
• Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. Febs J 2009;276(24):7228-36
   PubMed Web of Science ®Google Scholar
• Nara PL, Lin G. HIV-1: the confounding variables of virus neutralization. Curr Drug Targets Infect Disord 2005;5(2):157-70
   PubMedGoogle Scholar
• Araujo LA, Almeida SE. HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition. Viruses 2013;5(2):595-604
   PubMed Web of Science ®Google Scholar
• Luo M. Influenza virus entry. Adv Exp Med Biol 2012;726:201-21
   PubMed Web of Science ®Google Scholar
• Nagafuchi S, Oda H, Mori R, Taniguchi T. Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice. J Gen Virol 1979;44(3):715-23
   PubMedGoogle Scholar
• Oakes JE. Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection. Infect Immun 1975;12(1):166-72
   PubMed Web of Science ®Google Scholar
• Halford WP, Maender JL, Gebhardt BM. Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1. Virol J 2005;2:56
   PubMed Web of Science ®Google Scholar
• Theil D, Derfuss T, Paripovic I, et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003;163(6):2179-84
   PubMed Web of Science ®Google Scholar
• Morrison LA. Vaccines against genital herpes: progress and limitations. Drugs 2002;62(8):1119-29
   PubMed Web of Science ®Google Scholar
• Morrison LA, Zhu L, Thebeau LG. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J Virol 2001;75(3):1195-204
   PubMed Web of Science ®Google Scholar
• Chu CF, Meador MG, Young CG, et al. Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms. J Reprod Immunol 2008;78(1):58-67
   PubMed Web of Science ®Google Scholar
• Staats HF, Oakes JE, Lausch RN. Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. J Virol 1991;65(11):6008-14
   PubMed Web of Science ®Google Scholar
• Mackay LK, Stock AT, Ma JZ, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012;109(18):7037-42
   PubMed Web of Science ®Google Scholar
• Available from: http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HSV11–8-13.aspx 2013
   Google Scholar
• Morrison LA, Da Costa XJ, Knipe DM. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 1998;243(1):178-87
   PubMed Web of Science ®Google Scholar
• Reszka NJ, Dudek T, Knipe DM. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010;28(15):2754-62
   PubMed Web of Science ®Google Scholar
• Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 1999;96(12):6994-8
   PubMed Web of Science ®Google Scholar
• Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171(4356):737-8
   PubMed Web of Science ®Google Scholar
• Crick FH. On protein synthesis. Symp Soc Exp Biol 1958;12:138-63
   PubMedGoogle Scholar
• Schmid DS. Varicella-zoster virus vaccine: molecular genetics. Curr Top Microbiol Immunol 2010;342:323-40
   PubMed Web of Science ®Google Scholar
• Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One 2008;3(10):e3433
   PubMed Web of Science ®Google Scholar
• Nahmias AJ, Naib ZM, Josey WE. Epidemiological studies relating genital herpetic infection to cervical carcinoma. Cancer Res 1974;34(5):1111-17
   PubMed Web of Science ®Google Scholar
• Manos JP, Walker EM Jr. Viruses and human cancer. Ann Clin Lab Sci 1983;13(3):201-6
   PubMed Web of Science ®Google Scholar
• Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl 3):S3/1-10
   PubMedGoogle Scholar
• Halford WP, Schaffer PA. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J Virol 2001;75(7):3240-9
   PubMed Web of Science ®Google Scholar
• Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 2000;6(4):451-4
   PubMed Web of Science ®Google Scholar
• Takahashi M, Okuno Y, Otsuka T, et al. Development of a live attenuated varicella vaccine. Biken J 1975;18(1):25-33
   PubMedGoogle Scholar
• Goulleret N, Mauvisseau E, Essevaz-Roulet M, et al. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine 2010;28(36):5878-82
   PubMed Web of Science ®Google Scholar
• Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284(10):1271-9
   PubMed Web of Science ®Google Scholar
• Yamada M, Kamberos N, Grose C. Breakthrough varicella in a cancer patient with persistent varicella antibody after one varicella vaccination. J Pediatr 2013;163(5):1511-13
   PubMed Web of Science ®Google Scholar
• Fisher JP, Bate J, Hambleton S. Preventing varicella in children with malignancies: what is the evidence? Curr Opin Infect Dis 2011;24(3):203-11
   PubMed Web of Science ®Google Scholar
• Banovic T, Yanilla M, Simmons R, et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis 2011;204(12):1893-901
   PubMed Web of Science ®Google Scholar
• Chilek K, Routhouska S, Tamburro J. Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness. Pediatr Dermatol 2010;27(2):192-4
   PubMed Web of Science ®Google Scholar
• Harle P, Sainz B Jr, Carr DJ, Halford WP. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta. Virology 2002;293(2):295-304
   PubMed Web of Science ®Google Scholar
• Mossman KL, Saffran HA, Smiley JR. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 2000;74(4):2052-6
   PubMed Web of Science ®Google Scholar
• Leib DA, Harrison TE, Laslo KM, et al. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999;189(4):663-72
   PubMed Web of Science ®Google Scholar
• Everett RD, Boutell C, McNair C, et al. Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins. J Virol 2010;84(7):3476-87
   PubMed Web of Science ®Google Scholar
• Moffat JF, Zerboni L, Kinchington PR, et al. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 1998;72(2):965-74
   PubMed Web of Science ®Google Scholar
• Zerboni L, Hinchliffe S, Sommer MH, et al. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 2005;332(1):337-46
   PubMed Web of Science ®Google Scholar
• Horien C, Grose C. Neurovirulence of varicella and the live attenuated varicella vaccine virus. Semin Pediatr Neurol 2012;19(3):124-9
   PubMed Web of Science ®Google Scholar
• Prichard MN, Kaiwar R, Jackman WT, et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005;23(46–47):5424-31
   PubMed Web of Science ®Google Scholar
• Stephenson J. Genital herpes vaccine shows limited promise. JAMA 2000;284(15):1913-14
   PubMed Web of Science ®Google Scholar
• Wagner EK. 2000. Available from: http://darwin.bio.uci.edu/∼faculty/wagner/hsv3f.html
   Google Scholar